Dr Kesinee Chotivanich
Contact information
Podcast interview
Malaria laboratory at MORU
More effective diagnosis and treatments are needed to reduce the morbidity and mortality affecting malaria patients. Researchers at the Malaria Laboratory at MORU study the pathophysiology of the disease, and test new compound drugs for anti-malarial activity. In the context of growing artemisinin resistance, this research will have a global impact
Kesinee Chotivanich
Associate professor
Malaria laboratory
The MORU Malaria laboratory, Bangkok, Thailand provides facilities and resources to researchers, students, and collaborators who are interested in tropical diseases. We aim to generate new knowledge in order to improve patients’ care. Major research areas of interest are the pathophysiology of malaria, host-parasite interaction, the pharmacodynamics of antimalarial drugs, the mechanism of antimalarial drug resistance, and the development diagnostic tools. Currently, we have 5 PhD students and 9 scientists working in our laboratory.
Recent publications
-
Artemisinin-resistant malaria.
Journal article
White NJ. and Chotivanich K., (2024), Clin Microbiol Rev
-
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.
Journal article
Pukrittayakamee S. et al, (2024), Elife, 12
-
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
Journal article
Pukrittayakamee S. et al, (2024), eLife, 12
-
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Preprint
Wongnak P. et al, (2024)
-
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
Journal article
Luvira V. et al, (2024), BMC Infect Dis, 24